Aethlon Medical, Inc. (AEMD)

Over the past six months, Aethlon Medical's stock price has experienced significant volatility and a notable decrease, falling by -85.08% over the last six months and -86.61% over the last year. In November 2025, the company announced its fiscal Q2 2025 financial results, reporting an operating loss of $1.5 million and a cash balance of $5.8 million. In October 2025, the company provided observations on preliminary changes in extracellular vesicle, microRNA, and lymphocyte counts in the first patient cohort of its Australian oncology clinical trial, showing encouraging changes, and a 1-for-10 reverse stock split became effective. In September 2025, Aethlon Medical announced the pricing of a $4.5 million public offering of common stock and warrants and secured patents for the Hemopurifier's use in treating Long COVID and COVID-19-associated coagulopathy. In August 2025, the company announced financial results for its fiscal first quarter ended June 30, 2025, reporting a 31.6% reduction in operating expenses and progress in its Australian cancer trial, with the first cohort completed without device-related serious adverse events, leading to positive market sentiment. In July 2025, Aethlon Medical announced a positive Data Safety Monitoring Board review and recommendation to advance to the next clinical trial cohort in Australia. In June 2025, the company announced financial results for the fiscal fourth quarter ended March 31, 2025.

The demand for Aethlon Medical's products and services is primarily driven by medical necessity rather than seasonal trends, as the Hemopurifier is used to treat life-threatening conditions such as cancer and severe viral infections. There is no indication of any significant demand seasonality for Aethlon Medical's products or services.

Aethlon Medical, Inc. is a medical technology company focused on developing products to diagnose and treat life-threatening diseases, operating in the Health Care sector, specifically within the Medical/Dental Instruments and Medical Devices industries. The company is dedicated to developing novel immunotherapeutic devices to combat cancer and viral infections, with its primary product being the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device designed to remove cancer-promoting exosomes and life-threatening viruses from the circulatory system. The Hemopurifier has received a "Breakthrough Device" designation from the FDA for treating individuals with advanced or metastatic cancer and for life-threatening viruses not addressed by approved treatments. The company operates through two segments: Aethlon for therapeutic business activities and ESI for diagnostic business activities.

Aethlon Medical, Inc. is headquartered in San Diego, California, United States. The company is actively conducting clinical trials in Australia for its Hemopurifier in cancer patients and previously had a COVID-19 trial in India, which was discontinued to focus resources on the Australian study.

Aethlon Medical's brand reputation has been positively influenced by the FDA's "Breakthrough Device" designation for its Hemopurifier, the securing of patents for its use in treating Long COVID and COVID-19-associated coagulopathy, and positive outcomes from the first cohort of its Australian cancer trial. The company's collaboration with the University of California San Francisco on Long COVID research also highlights its engagement in addressing significant health challenges.

The ownership structure of Aethlon Medical (AEMD) stock is a mix of institutional, retail, and individual investors. Approximately 2.29% of the company's stock is owned by Institutional Investors, 54.40% by Insiders, and 43.31% by Public Companies and Individual Investors. Major institutional shareholders include Ikarian Capital, LLC, Hrt Financial Lp, Citadel Advisors Llc, Renaissance Technologies Llc, Scientech Research LLC, Two Sigma Investments, Lp, XTX Topco Ltd, Two Sigma Securities, Llc, Geode Capital Management, Llc, and Tower Research Capital LLC (TRC). Angela Rossetti owns the most shares among individual investors.